OCT 10, 2019 1:30 PM PDT

Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer

Speaker

Abstract

Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In this setting, many resistance mechanisms exist, driven both through the androgen receptor (AR) and independent of AR. In this resistant setting, more molecular biomarkers are now available to guide treatment selection. Of these, the AR-v7 splice variant of the androgen receptor can guide selection for chemotherapy based on the PROPHECY study. Furthermore, patients with mutations in DNA damage repair genes (particularly BRCA2, CDK12, BRCA1, CHEK2, and ATM) are especially susceptible to PARP inhibitors. PROfound, a recent phase 3 trial of mCRPC patients previously treated with docetaxel randomized to olaparib vs secondary hormonal inhibitors, showed improved progression free survival and ORR for olaparib. Patients with CDK12 loss and microsatellite instability also respond well to pembrolizumab, an immune checkpoint inhibitor. Therefore, given these targeted treatments outside of standard of care options, there is more impetus to perform genomic testing to evaluate for molecular biomarkers for mCRPC patients. This talk highlights these molecular alterations and treatment options in mCRPC.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
OCT 10, 2019 1:30 PM PDT

Precision oncology: Biomarkers for treatment selection in metastatic castration resistant prostate cancer



Show Resources
Loading Comments...
Show Resources
Attendees